We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis Boosts Heart Treatment Portfolio with $9.7 Billion Deal
Novartis Boosts Heart Treatment Portfolio with $9.7 Billion Deal
Novartis has forged a merger agreement with The Medicines Company under which it will buy up the firm’s cholesterol drug inclisiran for a whopping $9.7 billion.